ETFIQData as of Nov 18, 2026. · etfiq.com/funds/ftxh

FTXH Fact Sheet: First Trust Nasdaq Pharmaceuticals ETF

Share
$43.04
close, Nov 18, 2026

Over the year to Nov 18, 2026, FTXH returned +36.1% in total and charged 0.60% a year.

1-year total return
+36.1%
to Nov 18, 2026
Expense ratio
0.60%
a year
Net assets
$1.1bn
on Nov 17, 2026
Net flow, last 5 trading days
−$85.5m
daily basis to Nov 17, 2026

Growth of $10,000, 1 year

FTXH $13,607 +36.1% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month+3.5%
3 months+1.1%
Year to date+31.2%
1 year+36.1%
3 years+83.1%
5 years+74.0%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
Eli Lilly and Company8.35%
AbbVie Inc.7.79%
Johnson & Johnson7.15%
Pfizer Inc.6.82%
Merck & Co., Inc.6.62%
Viatris Inc.4.23%
Regeneron Pharmaceuticals, Inc.4.09%
Gilead Sciences, Inc.3.97%
Biogen Inc.3.95%
Zoetis Inc.3.69%

FTXH top ten by weight, 56.7% of the fund, of its 50 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Tracks the Nasdaq US Smart Pharmaceuticals Index · First traded Sep 22, 2016 · Benchmark Its own holdings, as of Nov 17, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, FTXH Fact Sheet: First Trust Nasdaq Pharmaceuticals ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/ftxh/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/ftxh.